Focal therapy for prostate cancer — the targeted ablation of the index lesion within the prostate without treating the entire gland, potentially offering the cancer control of local treatment with reduced side effects — creates an emerging specialized treatment market, with the Prostate Cancer Market reflecting focal therapy as an important developing commercial segment.

High-intensity focused ultrasound (HIFU) — the Sonablate (SonaCare Medical) and Focal One (EDAP TMS) systems using focused ultrasound to ablate prostate tissue at precisely targeted locations — represents the FDA-cleared focal therapy platform with the most commercial adoption. HIFU's non-invasive (transrectal application), repeatable nature, and growing clinical evidence supporting its role in select intermediate-risk patients creating the focal therapy commercial foundation.

Cryotherapy for prostate focal treatment — the Galil Medical (subsidiary BTG) focal cryotherapy using precise cryoprobe placement to ablate targeted prostate tissue — represents the focal ablation approach with established FDA clearance and long clinical history. Cryotherapy's more established reimbursement pathway compared to HIFU creating its commercial relevance in the focal therapy market.

MRI-guided focal therapy — the emerging integration of real-time MRI guidance with ablative technologies (focused ultrasound, laser ablation, cryotherapy) enabling the most precise focal treatment aligned with MRI-identified dominant lesions — represents the technology frontier of focal therapy. The Philips HIFU MRI-guided system and laser ablation approaches showing the direction of focal therapy evolution.

Do you think focal therapy will achieve guideline recognition as a standard treatment option for appropriate intermediate-risk prostate cancer, creating a major commercial treatment category, or will long-term comparative data versus surgery and radiation remain insufficient for mainstream adoption?

FAQ

What is focal therapy for prostate cancer and which technologies are used? Focal therapy: targeted ablation of prostate cancer index lesion while preserving uninvolved gland; rationale: prostate cancer often "unilateral" or focal by MRI; avoid whole-gland treatment side effects (incontinence, erectile dysfunction); technologies: HIFU (high-intensity focused ultrasound) — Sonablate, Focal One; Cryotherapy — Galil Medical; Laser interstitial thermal therapy (LITT); Irreversible electroporation (IRE/Nanoknife); MRI-guided focal laser ablation; patient selection: requires MRI-visible index lesion, low-intermediate risk, mpMRI confirming limited extent.

What clinical evidence supports HIFU for prostate focal therapy? HIFU focal therapy evidence: multiple prospective cohort studies from European centers (Emberton group UCL, Ahmed); five-year biochemical control comparable to whole-gland therapy in select patients; reduced side effects: erectile function preservation sixty to eighty percent versus thirty to forty percent radical prostatectomy; continence preservation ninety-plus percent; Limitations: lack of randomized controlled trials versus surgery/radiation; patient selection variable; medium-term oncological data limited; FDA clearance: Sonablate FDA cleared 2015, Focal One 2017; Medicare coverage: inconsistent (coverage determination varies by MAC); commercial growth: growing from HIFU-trained urology centers, patient demand for less invasive options.

#ProstateCancer #FocalTherapy #HIFU #ProstateFocal #ProstateCryotherapy #MinimallInvasiveProstate